• Molecular NamePefloxacin
  • SynonymNA
  • Weight333.363
  • Drugbank_IDDB00487
  • ACS_NO70458-92-3
  • Show 3D model
  • LogP (experiment)0.27
  • LogP (predicted, AB/LogP v2.0)-0.08
  • pkaN/A
  • LogD (pH=7, predicted)-1.64
  • Solubility (experiment)11.4 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-2.66
  • LogSw (predicted, AB/LogsW2.0)0.29
  • Sw (mg/ml) (predicted, ACD/Labs)0.58
  • No.of HBond Donors1
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds3
  • TPSA64.09
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA synthetic chemotherapeutic agent used to treat severe and life threatening bacterial infections.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability90.0
  • Protein binding25.0
  • Volume of distribution (VD)1~2.6 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmCytochrome P450 1A2 (CYP1A2) Hepatic metabolism is considerable. The main metabolites are demethylated pefloxacin, norfloxacin and pefloxacin N-oxide.
  • Half life8.6 h
  • ExcretionMostly renal, also biliary
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityAdverse reactions include peripheral neuropathy, nervousness, agitation, anxiety, and phototoxic events (rash, itching, burning) due to sunlight exposure.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A